Gracell Biotechnologies Inc. (NASDAQ:GRCL) Q1 2023 Earnings Conference Call May 15, 2023 8:00 AM ET

Company Participants

William Cao - Chairman, Chief Executive Officer

Wendy Li - Chief Medical Officer

Kevin Xie - Chief Financial Officer

Conference Call Participants

Yigal Nochomovitz - Citi

Emily Bodnar - HC Wainwright

Joe Cantanzaro - Piper Sandler

Dave - Jefferies

Wayne Wu - Cantor Fitzgerald

Yanan Zhu - Wells Fargo

Operator

Ladies and gentlemen, thank you for standing by and welcome to the Gracell Biotechnologies first quarter 2023 conference call. At this time, all participants are in a listen-only mode. After opening remarks, we will open the call for your questions. Instructions for queuing up will be given at that time.

I would now turn the conference call over to Dr. Kevin Xie, CFO. Please go ahead.

Kevin Xie

Good morning and welcome to Gracell’s first quarter 2023 corporate update conference call and webcast.

With me today are Gracell’s Founder and Chief Executive Officer, Dr. William Cao, and our Chief Medical Officer, Dr. Wendy Li. We’re excited to discuss the progress of our differentiated clinical pipeline of CAR-T therapies on today’s call. We also look forward to sharing with you our recent business development and upcoming objectives as we progress through 2023. We will conduct a question and answer session following our formal remarks.

This morning, Gracell issued a press release announcing unaudited financial results for the fourth quarter ended March 31, 2023. We encourage everyone to read this press release and would like to remind you that this call is being recorded for replay.

Please note that for certain information discussed on the call today, including financial data, clinical data, and the future plans of our program resource management, we will be making forward-looking statements. Actual results could differ materially from those stated our implied by those forward-looking statements as a result of various important factors. Please refer to the Risk Factors section of our latest 20-F filing with the SEC for full disclosure of these risks and factors.

This conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, May 15, 2023. Gracell undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities laws.

I will now turn the call over to Gracell’s CEO, Dr. William Cao. William?